Inbreeding coefficients and runs of homozygosity islands in Brazilian water buffalo
Characterization of autozygosity is related to observe genetic variety and handle inbreeding ranges in breeding packages. Identification of autozygosity hotspots can unravel genomic areas focused by choice for economically necessary traits and may help establish candidate genes for choice. In this examine, we estimated the inbreeding ranges of a Brazilian inhabitants of Murrah buffalo present process choice for milk manufacturing traits, significantly milk yield.
We additionally studied the distribution of runs of homozygosity (ROH) islands and recognized putative genes and quantitative trait loci (QTL) beneath choice. We genotyped 422 Murrah buffalo for 51,611 SNP; 350 of these had ROH longer than 10 Mb, indicating the incidence of inbreeding in the final 5 generations.
The imply size of the ROH per animal was 4.28 ± 1.85 Mb. Inbreeding coefficients have been calculated from the genomic relationship matrix, the pedigree, and the ROH, with estimates various between 0.242 and 0.035. Inbreeding estimates from the pedigree had a low correlation with the genomic estimates, and estimates from the genomic relationship matrix have been a lot increased than these from the pedigree or the ROH.
Signatures of choice have been recognized in 6 genomic areas, positioned on chromosomes 1, 2, 3, 5, 16, and 18, encompassing a complete of 190 genes and 174 QTL. Many of the genes (e.g., APRT and ACSF3) and QTL recognized are associated to exploit manufacturing traits, comparable to milk yield, milk fats yield and proportion, and milk protein yield and proportion. Other genes are related to replica and immune response traits in addition to morphological points of the buffalo species.
Inbreeding ranges in this inhabitants are nonetheless low however are growing resulting from choice and needs to be managed to keep away from future losses resulting from inbreeding melancholy. The proximity of genes linked to exploit manufacturing traits with genes related to replica and immune system traits suggests the necessity to embody these latter genes in the breeding program to keep away from negatively affecting them resulting from choice for manufacturing traits.
Genome-wide evaluation of homozygosity areas in european simmental bulls
The examine of Runs of Homozygosity (ROH) is a helpful strategy for the characterization of the genome of livestock populations. Due to their excessive relationship with autozygosity, ROH enable to make inference about inhabitants genetic historical past, to estimate the extent of inbreeding, to evaluate inside breed heterogeneity and to detect the footprints of choice on livestock genomes.
Aim of this examine was to analyze the distribution of runs of homozygosity in bulls belonging to 5 European Simmental populations and to evaluate the connection between three manufacturing traits (milk yield, fats and protein contents) and autozygosity. ROH rely, distribution and ROH-based coefficient of inbreeding (FROH ) have been calculated for 3,845 Simmental bulls of 5 totally different European nations: Austria (AT), Switzerland (CH), Czech Republic (CZ), Germany (DE) and Italy (IT).
Carcinoembryonic Antigen CEA |
TP1286-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
Description: Carcinoembryonic Antigen CEA |
Carcinoembryonic Antigen CEA |
TP1286-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
Description: Carcinoembryonic Antigen CEA |
Human carcinoembryonic antigen (CEA) antigen |
CEA15-N-100 |
Alpha Diagnostics |
100 ug |
EUR 270 |
Carcinoembryonic Antigen Protein |
20-abx262093 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Carcinoembryonic Antigen Protein |
abx262093-10mg |
Abbexa |
10 mg |
EUR 6575 |
Carcinoembryonic Antigen Protein |
abx262093-5mg |
Abbexa |
5 mg |
EUR 325 |
Carcinoembryonic Antigen (CEA) 95% |
GWB-19A52D |
GenWay Biotech |
0.1 mg |
Ask for price |
|
Carcinoembryonic Antigen (CEA) 98% |
GWB-1A3E2F |
GenWay Biotech |
1 mg |
Ask for price |
|
Carcinoembryonic Antigen (CEA) 95% |
GWB-621CF0 |
GenWay Biotech |
0.5 mg |
Ask for price |
Carcinoembryonic Antigen (CEA) 98% |
GWB-7EAB80 |
GenWay Biotech |
0.5 mg |
Ask for price |
Carcinoembryonic Antigen (CEA) 80% |
GWB-DE92F6 |
GenWay Biotech |
1 mg |
Ask for price |
Carcinoembryonic Antigen Antibody |
38106 |
SAB |
100ul |
EUR 319 |
Carcinoembryonic Antigen Antibody |
38106-100ul |
SAB |
100ul |
EUR 302.4 |
Carcinoembryonic Antigen Antibody |
38106-50ul |
SAB |
50ul |
EUR 224.4 |
Carcinoembryonic Antigen Antibody |
E038106 |
EnoGene |
100μg/100μl |
EUR 255 |
Description: Available in various conjugation types. |
Recombinant Carcinoembryonic Antigen |
VAng-Cr3880-1mg |
Creative Biolabs |
1 mg |
EUR 2188.8 |
Description: Recombinant Carcinoembryonic Antigen, Host/Source: Mammalian Cell Expression System. The purity is> 95% by SDS-PAGE. |
Active Carcinoembryonic Antigen (CEA) |
APA150Hu02 |
Cloud-Clone |
10ug |
EUR 204 |
Active Carcinoembryonic Antigen (CEA) |
APA150Hu04 |
Cloud-Clone |
10ug |
EUR 245 |
Active Carcinoembryonic Antigen (CEA) |
4-APA150Hu04 |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Carcinoembryonic Antigen expressed in: Available from E.coli, Yeast, Baculovirus and Mammalian cells |
Carcinoembryonic Antigen (CEA ) Antibody |
E12-76010 |
EnoGene |
100μg/100μl |
EUR 255 |
Description: Available in various conjugation types. |
Carcinoembryonic Antigen (CEA ) Antibody |
E76010-2 |
EnoGene |
100μg/100μl |
EUR 225 |
Description: Available in various conjugation types. |
CEA (Carcinoembryonic antigen) Antibody |
E80807-10 |
EnoGene |
100μl |
EUR 225 |
Description: Available in various conjugation types. |
Carcinoembryonic Antigen (CEA) Antibody |
E63C00301a |
EnoGene |
100μg/100μl |
EUR 225 |
Description: Available in various conjugation types. |
Carcinoembryonic Antigen (CEA) Antibody |
20-abx270133 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 tests
- 200 tests
- 25 tests
- 500 tests
- 50 tests
|
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx270165 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 tests
- 200 tests
- 25 tests
- 500 tests
- 50 tests
|
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx270190 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 tests
- 200 tests
- 25 tests
- 500 tests
- 50 tests
|
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx175703 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx171571 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx171572 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx128498 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx128499 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Carcinoembryonic Antigen (CEA) Antibody |
abx231576-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Carcinoembryonic Antigen (CEA) Antibody |
abx120020-1mg |
Abbexa |
1 mg |
EUR 944.4 |
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx102321 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx102322 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx102323 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Carcinoembryonic Antigen (CEA) Antibody |
20-abx102324 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Carcinoembryonic Antigen (CEA) Antibody |
abx020536-1mg |
Abbexa |
1 mg |
EUR 944.4 |
|
Carcinoembryonic Antigen (CEA) Antibody |
abx020540-1mg |
Abbexa |
1 mg |
EUR 944.4 |
|
Carcinoembryonic Antigen (CEA) Antibody |
abx020541-1mg |
Abbexa |
1 mg |
EUR 910.8 |
|
Carcinoembryonic Antigen (CEA) Antibody |
abx020542-1mg |
Abbexa |
1 mg |
EUR 828 |
|
Carcinoembryonic Antigen (CEA) Antibody |
abx020543-1mg |
Abbexa |
1 mg |
EUR 886.8 |
|
Carcinoembryonic Antigen (CEA) Antibody |
abx020544-1mg |
Abbexa |
1 mg |
EUR 828 |
|
Carcinoembryonic Antigen (CEA) Antibody |
abx020545-1mg |
Abbexa |
1 mg |
EUR 828 |
|
Carcinoembryonic Antigen (CEA) Antibody |
abx020546-1mg |
Abbexa |
1 mg |
EUR 828 |
|
Carcinoembryonic Antigen (CEA) Antibody |
abx022526-01ml |
Abbexa |
0.1 ml |
EUR 1328.4 |
|
Carcinoembryonic Antigen (CEA), Antibody |
GWB-A40F76 |
GenWay Biotech |
1 mg |
Ask for price |
Carcinoembryonic Antigen (CEA), Antibody |
GWB-B5942C |
GenWay Biotech |
1 mg |
Ask for price |
Carcinoembryonic Antigen (CEA), Antibody |
GWB-B77575 |
GenWay Biotech |
1 mg |
Ask for price |
CEA Antibody / Carcinoembryonic Antigen |
RQ5159 |
NSJ Bioreagents |
100ul |
EUR 356.15 |
|
Description: This gene encodes a cell surface glycoprotein that represents the founding member of the carcinoembryonic antigen (CEA) family of proteins. The encoded protein is used as a clinical biomarker for gastrointestinal cancers and may promote tumor development through its role as a cell adhesion molecule. [RefSeq] |
Carcinoembryonic Antigen (CEA) Antibody |
GWB-T00426 |
GenWay Biotech |
1 mg |
Ask for price |
Carcinoembryonic Antigen (CEA) Antibody |
GWB-T00427 |
GenWay Biotech |
1 mg |
Ask for price |
Carcinoembryonic Antigen (CEA) Antibody |
GWB-T00428 |
GenWay Biotech |
1 mg |
Ask for price |
Carcinoembryonic Antigen (CEA) Antibody |
GWB-T00429 |
GenWay Biotech |
1 mg |
Ask for price |
Carcinoembryonic Antigen (CEA) Antibody |
GWB-T00430 |
GenWay Biotech |
1 mg |
Ask for price |
Carcinoembryonic Antigen (CEA) Antibody |
GWB-T00431 |
GenWay Biotech |
1 mg |
Ask for price |
Carcinoembryonic Antigen (CEA), Antibody |
GWB-7FB0D0 |
GenWay Biotech |
1 mg |
Ask for price |
Carcinoembryonic Antigen (CEA), Antibody |
GWB-674DDD |
GenWay Biotech |
1 mg |
Ask for price |
CEA Antibody / Carcinoembryonic Antigen |
R20351-0.1ML |
NSJ Bioreagents |
100ul |
EUR 409 |
CEA Antibody / Carcinoembryonic Antigen |
V8631-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: The CD66 (carcinoembryonic antigen, CEA, biliary glycoprotein I, BGP-1, CEACAM) immunoglobulin superfamily of genes encode cell adhesion proteins, which are expressed at higher levels in tumorous tissues than in normal tissues. The human CD66 gene family is a diverse set of glycoproteins of epithelial and hematopoietic lineage that comprises 29 genes, which map to chromosome position 19q13.2. CD66A, CD66B, CD66C, CD66D, CD66E and CD66F are the best characterized CD66 antigens, and CD66A-D expression upregulates on the surface of granulocytes upon stimulation. Certain CD66 family members mediate homotypic and heterotypic intercellular adhesion events. CD66E, also known as CEA, is a well known tumor marker and a heavily glycosylated GPI-linked cell surface molecule. |
CEA Antibody / Carcinoembryonic Antigen |
V8631-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: The CD66 (carcinoembryonic antigen, CEA, biliary glycoprotein I, BGP-1, CEACAM) immunoglobulin superfamily of genes encode cell adhesion proteins, which are expressed at higher levels in tumorous tissues than in normal tissues. The human CD66 gene family is a diverse set of glycoproteins of epithelial and hematopoietic lineage that comprises 29 genes, which map to chromosome position 19q13.2. CD66A, CD66B, CD66C, CD66D, CD66E and CD66F are the best characterized CD66 antigens, and CD66A-D expression upregulates on the surface of granulocytes upon stimulation. Certain CD66 family members mediate homotypic and heterotypic intercellular adhesion events. CD66E, also known as CEA, is a well known tumor marker and a heavily glycosylated GPI-linked cell surface molecule. |
CEA Antibody / Carcinoembryonic Antigen |
V8631SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: The CD66 (carcinoembryonic antigen, CEA, biliary glycoprotein I, BGP-1, CEACAM) immunoglobulin superfamily of genes encode cell adhesion proteins, which are expressed at higher levels in tumorous tissues than in normal tissues. The human CD66 gene family is a diverse set of glycoproteins of epithelial and hematopoietic lineage that comprises 29 genes, which map to chromosome position 19q13.2. CD66A, CD66B, CD66C, CD66D, CD66E and CD66F are the best characterized CD66 antigens, and CD66A-D expression upregulates on the surface of granulocytes upon stimulation. Certain CD66 family members mediate homotypic and heterotypic intercellular adhesion events. CD66E, also known as CEA, is a well known tumor marker and a heavily glycosylated GPI-linked cell surface molecule. |
CEA Antibody / Carcinoembryonic Antigen |
V8890-100UG |
NSJ Bioreagents |
100ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V8890-20UG |
NSJ Bioreagents |
20ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V8890SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9002-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9002-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9002IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9002SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9003-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9003-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9003IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9003SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9008-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9008-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9008IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9008SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9164-100UG |
NSJ Bioreagents |
100ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9164-20UG |
NSJ Bioreagents |
20ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9164SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V3716-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Therefore, CEA is usually present only at very low levels in the blood of healthy adults. However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. [Wiki] |
CEA Antibody / Carcinoembryonic Antigen |
V3716-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Therefore, CEA is usually present only at very low levels in the blood of healthy adults. However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. [Wiki] |
CEA Antibody / Carcinoembryonic Antigen |
V3716IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
|
Description: Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Therefore, CEA is usually present only at very low levels in the blood of healthy adults. However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. [Wiki] |
CEA Antibody / Carcinoembryonic Antigen |
V3716SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Therefore, CEA is usually present only at very low levels in the blood of healthy adults. However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. [Wiki] |
CEA Antibody / Carcinoembryonic Antigen |
V4046-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V4046-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V4046SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V7069-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). |
CEA Antibody / Carcinoembryonic Antigen |
V7069-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). |
CEA Antibody / Carcinoembryonic Antigen |
V7069IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). |
CEA Antibody / Carcinoembryonic Antigen |
V7069SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). |
CEA Antibody / Carcinoembryonic Antigen |
V2375-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2375-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2375IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2375SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2376-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200 kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2376-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200 kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2376CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2376IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200 kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2376SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200 kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2444-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA). It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2444-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA). It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2444IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA). It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2444SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA). It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2445-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA) and shows a cross-reaction with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2445-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA) and shows a cross-reaction with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2445SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA) and shows a cross-reaction with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2446-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA) and shows a cross-reaction with human polymorphonuclear leukocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2446-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA) and shows a cross-reaction with human polymorphonuclear leukocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2446IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA) and shows a cross-reaction with human polymorphonuclear leukocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2446SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA) and shows a cross-reaction with human polymorphonuclear leukocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2447-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2447-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2447IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2447SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2087-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: The COL-1 antibody recognizes proteins of 80-200kDa, identified as different members of the Carcinoembryonic Antigen family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. CEA antibody is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are positive) from pleural mesotheliomas (rarely or weakly positive). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2087-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: The COL-1 antibody recognizes proteins of 80-200kDa, identified as different members of the Carcinoembryonic Antigen family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. CEA antibody is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are positive) from pleural mesotheliomas (rarely or weakly positive). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2087IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: The COL-1 antibody recognizes proteins of 80-200kDa, identified as different members of the Carcinoembryonic Antigen family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. CEA antibody is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are positive) from pleural mesotheliomas (rarely or weakly positive). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2087SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: The COL-1 antibody recognizes proteins of 80-200kDa, identified as different members of the Carcinoembryonic Antigen family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. CEA antibody is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are positive) from pleural mesotheliomas (rarely or weakly positive). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2088-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2088-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2088IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2088SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2089-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2089-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2089IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V2089SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of the CEA (Carcinoembryonic Antigen) family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This antibody does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. The antibody shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA antibody positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9318-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9318-20UG |
NSJ Bioreagents |
20ug |
EUR 153.3 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V9318SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V8370-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Carcinoembryonic antigen (CEA) is a glycoprotein produced in colorectal cancer tissues. In normal adult tissue, CEA is expressed in the apical border and, to a lesser extent in the cytoplasm, of the columnar cells of colon, small intestine, stomach (surface epithelium, mucous neck cells and weakly in pyloric mucous cells), pancreatic ducts, secretory epithelia of sweat glands, squamous epithelial cells of the tongue, esophagus,uterine cervix, and urothelium. The CEA antibody is a useful aid for classification of adenocarcinomas, notably in the gastrointestinal tract, including colonic and pancreatic carcinomas. IHC results also aid in the classification of secretory meningiomas and medullary carcinoma of the thyroid. |
CEA Antibody / Carcinoembryonic Antigen |
V8370-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: Carcinoembryonic antigen (CEA) is a glycoprotein produced in colorectal cancer tissues. In normal adult tissue, CEA is expressed in the apical border and, to a lesser extent in the cytoplasm, of the columnar cells of colon, small intestine, stomach (surface epithelium, mucous neck cells and weakly in pyloric mucous cells), pancreatic ducts, secretory epithelia of sweat glands, squamous epithelial cells of the tongue, esophagus,uterine cervix, and urothelium. The CEA antibody is a useful aid for classification of adenocarcinomas, notably in the gastrointestinal tract, including colonic and pancreatic carcinomas. IHC results also aid in the classification of secretory meningiomas and medullary carcinoma of the thyroid. |
CEA Antibody / Carcinoembryonic Antigen |
V8370SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Carcinoembryonic antigen (CEA) is a glycoprotein produced in colorectal cancer tissues. In normal adult tissue, CEA is expressed in the apical border and, to a lesser extent in the cytoplasm, of the columnar cells of colon, small intestine, stomach (surface epithelium, mucous neck cells and weakly in pyloric mucous cells), pancreatic ducts, secretory epithelia of sweat glands, squamous epithelial cells of the tongue, esophagus,uterine cervix, and urothelium. The CEA antibody is a useful aid for classification of adenocarcinomas, notably in the gastrointestinal tract, including colonic and pancreatic carcinomas. IHC results also aid in the classification of secretory meningiomas and medullary carcinoma of the thyroid. |
CEA Antibody / Carcinoembryonic Antigen |
V3527-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA). It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V3527-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA). It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
CEA Antibody / Carcinoembryonic Antigen |
V3527SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA). It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix. |
Average values of ROH quantity per animal, and whole genome size lined by ROH have been 77.8 ± 20.7 and 205 ± 74.4 Mb, respectively. Bulls from AT, DE and IT exhibited comparable ROH traits. Swiss animals confirmed the best (12.6%), whereas CZ the bottom (4.6%) FROH coefficient.
The relationship between ROH incidence and milk manufacturing traits was investigated by means of a genome-wide ROH-traits affiliation evaluation (GWRA). A complete of 34 areas beforehand related to milk traits (yield and/or composition) have been recognized by GWRA.
Results of the current analysis spotlight a combined genetic background in the 5 European Simmental populations, with the doable presence of three subgroups. Moreover, a robust relationship between autozygosity and manufacturing traits has been detected.